New radioactive tracers could spot cancers more clearly

NCT ID NCT07639970

Not yet recruiting Diagnosis Sponsor: Hua Pang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is to see if the tracers are safe and can help doctors see tumors more clearly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radioactive tracers (68Ga-HT547 and 177Lu-HT547)
What this could lead to: If successful, this could lead to a more accurate way to detect and monitor certain solid tumors using imaging scans.
What could go wrong: This is a very early, small study (20 people) focused on safety and imaging, not treatment. It may not lead to better outcomes for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm glioma head and neck cancer Head and Neck Neoplasms malignant pancreatic neoplasm neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER GLIOMA HEAD AND NECK CANCER (H&N) PANCREATIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.